Company intelligence / Profile preview

Oncternal Therapeutics

San Diego, California, United Statesoncternal.com ↗

Ownership: Public · ONCT
Employees: ~30
Development stage: Phase 1

Overview

The company discontinued all clinical trials on September 12, 2024, after disappointing data and a patient death in the ONCT-808 trial. ONCT-808 had shown antitumor activity at all dose levels tested with a complete metabolic response lasting 8 months, but one patient died from complications of shock at the highest dose tested. ONCT-534 failed to show meaningful disease improvements in an interim Phase 1/2 analysis.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodiesCAR-T cell therapySmall moleculesDual-Action Androgen Receptor Inhibitors (DAARI)
Industry: Biotech

Drug pipeline

7 assets

TK216

6 more assets in the full pipeline.

Request access →

Financials

Market cap: $1.6M
Total revenue: $494K
Enterprise value: $-12.8M

Beyond the preview

Go deeper on Oncternal Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oncternal Therapeutics.

Explore the full profile